Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:ASTNYSE:MENNASDAQ:PET On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsMENBlackRock MuniEnhanced Fund$12.08$12.01$9.95▼$12.57N/AN/A55,540 shs28,963 shsPETWag! Group$0.16-4.7%$0.14$0.08▼$1.69$8.37M1.663.00 million shs1.48 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASTAsterias Biotherapeutics0.00%0.00%0.00%0.00%0.00%MENBlackRock MuniEnhanced Fund0.00%0.00%0.00%0.00%0.00%PETWag! Group0.00%+55.24%+11.57%+46.45%-89.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMENBlackRock MuniEnhanced FundN/AN/AN/AN/AN/AN/AN/AN/APETWag! Group2.6208 of 5 stars3.32.00.00.02.93.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASTAsterias Biotherapeutics 0.00N/AN/AN/AMENBlackRock MuniEnhanced Fund 0.00N/AN/AN/APETWag! Group 2.60Moderate Buy$4.172,456.24% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AMENBlackRock MuniEnhanced FundN/AN/AN/AN/AN/AN/APETWag! Group$70.51M0.12N/AN/A($0.01) per share-16.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AMENBlackRock MuniEnhanced FundN/AN/A0.00∞N/AN/AN/AN/AN/APETWag! Group-$17.57M-$0.39N/A∞N/A-29.17%N/A-58.54%8/6/2025 (Estimated)Latest MEN, CLON, AST, and PET EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025PETWag! Group-$0.07-$0.10-$0.03-$0.10$19.30 million$15.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AMENBlackRock MuniEnhanced Fund$0.584.80%N/AN/AN/APETWag! GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASTAsterias BiotherapeuticsN/AN/AN/AMENBlackRock MuniEnhanced FundN/AN/AN/APETWag! GroupN/A0.460.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASTAsterias BiotherapeuticsN/AMENBlackRock MuniEnhanced FundN/APETWag! Group86.16%Insider OwnershipCompanyInsider OwnershipASTAsterias BiotherapeuticsN/AMENBlackRock MuniEnhanced FundN/APETWag! Group20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableMENBlackRock MuniEnhanced FundN/AN/AN/ANot OptionablePETWag! Group9050.74 million40.24 millionNot OptionableMEN, CLON, AST, and PET HeadlinesRecent News About These CompaniesWag Group (NASDAQ:PET) Stock, Short Interest ReportJuly 1, 2025 | benzinga.comWag! Group Co. (PET) - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comWag! Group Co News (PET) - Investing.comJune 28, 2025 | investing.comPets Supplies Plus and Wag N’ Wash in Livonia on Pace to Open 25 Stores by End of YearJune 10, 2025 | dbusiness.comDPet Supplies Plus and Wag N' Wash Report Double Digit Mid-Year Growth Amid Record Industry HighsJune 9, 2025 | finance.yahoo.comWilliston Animal Group to host Puppy Palooza on SaturdayMay 22, 2025 | mainstreetdailynews.comMEarnings call transcript: Wag! Group Co Q1 2025 sees revenue dip, cost cutsMay 13, 2025 | uk.investing.comWag! Group Co. (NASDAQ:PET) Q1 2025 Earnings Call TranscriptMay 13, 2025 | insidermonkey.comWag Group Co (PET) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Cost Management ...May 13, 2025 | finance.yahoo.comWag! Group outlines $84M–$88M 2025 revenue target as distribution partnerships go liveMay 12, 2025 | msn.comWag! Group Co. (PET) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comWag! Reports First Quarter 2025 ResultsMay 12, 2025 | manilatimes.netMWag! Group Co. (NASDAQ:PET) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | msn.comWag! Group (PET) Gets a Hold from Craig-HallumMarch 25, 2025 | markets.businessinsider.comWag! Group Stock Jumps After-Hours As Board Weighs Strategic Moves: Retail Bulls PounceMarch 25, 2025 | msn.comWag! group outlines $84M-$88M revenue target for 2025 amid new partnerships and AI integrationMarch 24, 2025 | msn.comWag! Group Co. (PET) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | seekingalpha.comWag! Reports Fourth Quarter and Full Year 2024 Results; Announces Review of Strategic Alternatives to Maximize Shareholder ValueMarch 24, 2025 | globenewswire.comWag! To Report Fourth Quarter and Full Year 2024 Financial Results on March 24, 2025March 18, 2025 | globenewswire.comInsider Selling: Wag! Group Co. (NASDAQ:PET) CTO Sells 38,144 Shares of StockFebruary 20, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI Spending3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not Hype3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBreakout Momentum Plays You May Not Know AboutBy Nathan Reiff | June 6, 2025View Breakout Momentum Plays You May Not Know AboutMEN, CLON, AST, and PET Company DescriptionsAsterias Biotherapeutics NYSEAMERICAN:AST$0.0020 0.00 (0.00%) As of 07/10/2019Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.BlackRock MuniEnhanced Fund NYSE:MENBlackRock MuniEnhanced Fund, Inc. operates as a closed-end investment fund. The firm intends to provide shareholders with current income exempt from federal income taxes. It invests in long-term municipal bonds rated investment grade quality at the time of investment and invests primarily in long-term municipal bonds with maturities over the time of investment. The company was founded on March 2, 1989 and is headquartered in Wilmington, DE.Wag! Group NASDAQ:PET$0.16 -0.01 (-4.68%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.16 0.00 (0.00%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wag! Group Co. develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent pet caregivers to connect with pet parents. Its platform allows pet parents, who require specific pet care services, such as dog walking, pet sitting and boarding, advice from licensed pet experts, home visits, training, and pet insurance comparison tools. The company was founded in 2014 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
